title: A new substrate for sampling deep river macroinvertebrates

authors: Collier, Kevin J.

subjects: Hester-Dendy

abstract: We compared macroinvertebrate communities colonising multiplate samplers constructed from perspex or tempered hardboard (wood) with an alternative artificial substrate constructed from folded coconut fibre matting (coir) enclosed in nylon netting. Substrates were incubated for 62 days over January to March 2007 at six sites over 240 km along the Waikato River. The three substrates supported similar numbers of invertebrate taxa (27 - 29 taxa), but coir samples contained 71% of total invertebrate numbers from all substrates combined, compared with <17% for each type of multiplate sampler. Coir faunas were heavily dominated by the hydrobiid snail Potamopyrgus (84 % of numbers), and this taxon along with the amphipod Paracalliope comprised 58 - 66 % of invertebrates on both types of multiplate samplers. Analysis of a Bray-Curtis matrix suggested statistically significant differences in percent community composition between coir samplers and each type of multiplate sampler over the late summer study period. Densities per cm3 of Oligochaeta, Mollusca, and "other worms" (Platyhelminthes, Rhabdocoela, Nemertea and Hirudinea combined) were significantly higher in coir samples than one or both of the multiplate samplers. Results suggest coir samplers may provide a useful supplement to multiplate samplers for deep river invertebrate studies by collecting a different range of taxa, including those favouring cover and characteristic of depositional environments.

text: A new substrate for sampling deep river macroinvertebrates We compared macroinvertebrate communities colonising multiplate samplers constructed from perspex or tempered hardboard (wood) with an alternative artificial substrate constructed from folded coconut fibre matting (coir) enclosed in nylon netting. Substrates were incubated for 62 days over January to March 2007 at six sites over 240 km along the Waikato River. The three substrates supported similar numbers of invertebrate taxa (27 - 29 taxa), but coir samples contained 71% of total invertebrate numbers from all substrates combined, compared with <17% for each type of multiplate sampler. Coir faunas were heavily dominated by the hydrobiid snail Potamopyrgus (84 % of numbers), and this taxon along with the amphipod Paracalliope comprised 58 - 66 % of invertebrates on both types of multiplate samplers. Analysis of a Bray-Curtis matrix suggested statistically significant differences in percent community composition between coir samplers and each type of multiplate sampler over the late summer study period. Densities per cm3 of Oligochaeta, Mollusca, and "other worms" (Platyhelminthes, Rhabdocoela, Nemertea and Hirudinea combined) were significantly higher in coir samples than one or both of the multiplate samplers. Results suggest coir samplers may provide a useful supplement to multiplate samplers for deep river invertebrate studies by collecting a different range of taxa, including those favouring cover and characteristic of depositional environments.

year: 2009

title: Modern Biotechnology in New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99

authors: Marsh, Dan

subjects: biotechnology

abstract: The New Zealand Government has indicated a strong interest in fostering innovation and aims to concentrate on selected areas where New Zealand may be able to develop a new comparative advantage. One such area is biotechnology, which would build on New Zealand's existing comparative advantage in the primary sector dairy, forestry, meat, wool and horticulture). This paper aims to fill some of the gaps in our knowledge of biotechnology and innovation processes in New Zealand. It is based on the 1998/99 survey of modern biotechnology activity in New Zealand conducted by Statistics New Zealand in 2000. The survey was commissioned by the Ministry of Research, Science and Technology (MORST) mainly in order to produce statistics on the present position of the industry for planning purposes. The findings reported in this paper are based on further analysis of the survey data conducted by the author on behalf of MORST. Data are presented on the number, type and characteristics of enterprises involved in biotechnology in New Zealand. The paper presents data on enterprises that conduct R&D into modern biotech processes and includes analysis of the rate of innovation by biotech respondents compared to OECD estimates. Comparisons are also made between data from the New Zealand and Canadian biotech surveys.

text: Modern Biotechnology in New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99 The New Zealand Government has indicated a strong interest in fostering innovation and aims to concentrate on selected areas where New Zealand may be able to develop a new comparative advantage. One such area is biotechnology, which would build on New Zealand's existing comparative advantage in the primary sector dairy, forestry, meat, wool and horticulture). This paper aims to fill some of the gaps in our knowledge of biotechnology and innovation processes in New Zealand. It is based on the 1998/99 survey of modern biotechnology activity in New Zealand conducted by Statistics New Zealand in 2000. The survey was commissioned by the Ministry of Research, Science and Technology (MORST) mainly in order to produce statistics on the present position of the industry for planning purposes. The findings reported in this paper are based on further analysis of the survey data conducted by the author on behalf of MORST. Data are presented on the number, type and characteristics of enterprises involved in biotechnology in New Zealand. The paper presents data on enterprises that conduct R&D into modern biotech processes and includes analysis of the rate of innovation by biotech respondents compared to OECD estimates. Comparisons are also made between data from the New Zealand and Canadian biotech surveys.

year: 2001-01

title: Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand

authors: Chepulis, Lynne Merran

subjects: GLP1RA

abstract: Background: Type 2 diabetes (T2D) is sub-optimally managed for many in Aotearoa New Zealand, and disproportionately affects Māori and Pacific peoples. In February 2021, SGLT2i/GLP1RA agents were funded for use for the first time with prioritisation for Māori, Pacific and those with cardiovascular and/or renal disease or risk (CVRD). This study evaluates the impact of health system factors on initiation of SGLT2i/GLP1RA therapy. 

Methods: Primary care data was collected for patients with T2D aged 18–75 years from four primary care organisations (302 general practices) in the Auckland / Waikato region of New Zealand (Feb 2021 – July 2022). Initiation of SGLT2i/GLP1RA therapy was reviewed by patient (age, gender, ethnicity, CVRD status) and health system variables (funding, provider type, staffing, patient numbers, rurality, after-hours access). Logistic regression was used to estimate the odds ratio of a patient being dispensed SGLT2i/GLP1RA. 

Results: Of 57,743 patients with T2D, 22,331 were eligible for funded SGLT2i/GLP1RA access and 10,272 of those (46.0%) were prescribed. Initiation of therapy was highest in Māori (50.8%) and Pacific (48.8%) patients (vs. 36·2–40·7% of other ethnic groups; P < 0.001), but was comparable in those with and without CVRD (47·1% vs. 48·9%; P = 0.2). Prescribing was highest in practices with higher doctor/patient numbers, low-cost fees, Māori health providers and clinics without after-hours access.

Conclusion: Prioritised access for SGLT2i/GLP1RA appears to be associated with a reduced health equity gap for Māori and Pacific patients with T2D in NZ, but work is required to improve prescribing for patients with CVRD.

text: Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand Background: Type 2 diabetes (T2D) is sub-optimally managed for many in Aotearoa New Zealand, and disproportionately affects Māori and Pacific peoples. In February 2021, SGLT2i/GLP1RA agents were funded for use for the first time with prioritisation for Māori, Pacific and those with cardiovascular and/or renal disease or risk (CVRD). This study evaluates the impact of health system factors on initiation of SGLT2i/GLP1RA therapy. 

Methods: Primary care data was collected for patients with T2D aged 18–75 years from four primary care organisations (302 general practices) in the Auckland / Waikato region of New Zealand (Feb 2021 – July 2022). Initiation of SGLT2i/GLP1RA therapy was reviewed by patient (age, gender, ethnicity, CVRD status) and health system variables (funding, provider type, staffing, patient numbers, rurality, after-hours access). Logistic regression was used to estimate the odds ratio of a patient being dispensed SGLT2i/GLP1RA. 

Results: Of 57,743 patients with T2D, 22,331 were eligible for funded SGLT2i/GLP1RA access and 10,272 of those (46.0%) were prescribed. Initiation of therapy was highest in Māori (50.8%) and Pacific (48.8%) patients (vs. 36·2–40·7% of other ethnic groups; P < 0.001), but was comparable in those with and without CVRD (47·1% vs. 48·9%; P = 0.2). Prescribing was highest in practices with higher doctor/patient numbers, low-cost fees, Māori health providers and clinics without after-hours access.

Conclusion: Prioritised access for SGLT2i/GLP1RA appears to be associated with a reduced health equity gap for Māori and Pacific patients with T2D in NZ, but work is required to improve prescribing for patients with CVRD.

year: 2025